Methepitiostane was first described in 1966, during investigations into a series of A-ring modified androstane derivatives. That same year it was assayed for anabolic and androgenic potency via the standard rat assays, and demonstrated both pronounced anabolic properties and very weak relative androgenicity. The assay results were probably most similar to desoxymethyltestosterone (Madol), although methepitiostane is about half as androgenic. Although the results of the early testing were very favorable, this agent never progressed to the point of being a commercial steroid product or even tested on human subjects. Like a great many steroids, it was examined but not actualized as a prescription product. For forty years, the agent would be lost to the public, existing as an item of research interest only.
Methepitiostane would emerge from research obscurity at the end of 2006, when a new company called Recomp Performance Nutrition introduced it to the U.S. market under the trade name Havoc. It would be sold openly as a dietary supplement. This channel of sales does not reflect a weak potency or "non-steroid" classification, however, as methepitibstane is very much a potent drug. It is being sold as such due to the fact that the U.S. dietary supplement market is not tightly regulated, and the drug was never classified (specifically according to the law) as an anabolic steroid. While regulations do exist that would prevent the sale of an unapproved new drug as a food supplement, they do not carry the same weight as the anabolic steroid laws, and have historically not been aggressively enforced. Methepitiostane remains on sale as of December 2006, although the manufacturer has stated that they plan to discontinue the product very shortly.
How is Havoc Supplied
Methepitiostane was never approved as a prescription drug preparation. It is being sold in the U.S. supplement market under the trade name Havoc, and is supplied in the form of capsules containing 10 mg of steroid.
Structural Characteristics of Havoc
Methepitiostane is a modified form of dihydrotestosterone. It differs by 1) the addition of a 17-alpha methyl group, which helps protect the steroid from metabolism during oral administration, and 2) the replacement of 3-keto with 2,3alpha-epithio, which increases anabolic strength while reducing relative androgenicity.
Havoc Side Effects (Estrogenic)
Methepitiostane is not aromatized by the body, and is not measurably estrogenic. Furthermore, its non-methylated analog mepitiostane (Thioderon) is used clinically for its inherent antiestrogenic effect. Some level of antiestrogenic effect is also assumed with methepitiostane. An antiestrogen is, likewise, not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns. Note that some users may notice lethargy with this steroid, which may be due, in part, to its low androgenic or estrogenic component. Stacking it with an aromatizable androgen like testosterone should alleviate this problem.
Havoc Side Effects (Androgenic)
Although classified as an anabolic steroid, androgenic side effects are still possible with this substance, especially with higher doses. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Methepitiostane is a steroid with very low androgenic activity relative to its tissue-building actions, making the threshold for strong androgenic side effects comparably higher than with more androgenic agents such as testosterone, methandrostenolone, or fluoxymesterone. Note that methepitiostane is unaffected by the 5-alpha reductase enzyme, so its relative androgenicity is not affected by the concurrent use of finasteride or dutasteride.
Havoc Side Effects (Hepatotoxicity)
Methepitiostane is a cl 7-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. Cl 7-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of cl 7-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
Havoc Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Methepitiostane has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown, non-aromatizable nature, and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
Havoc Administration (Men)
Methepitiostane was never approved for use in humans. Prescribing guidelines are unavailable. An effective dosage for physique- or performance enhancing purposes falls in the range of 10-20 mg daily. This is usually taken for no longer than 6-8 weeks, in an effort to avoid significant liver strain. At this level the drug should impart a measurable but moderate lean-mass-building effect, which, depending on dietary and metabolic factors, may be accompanied by measurable fat loss and an increase in definition. Doses of 30 mg per day are also commonly used, however given the high relative potency of the steroid may present significant hepatotoxicity. When administered, higher doses are usually taken for durations lasting no longer than 4-6 weeks.
Havoc Administration (Women)
Methepitiostane was never approved for use in humans. Prescribing guidelines are unavailable. An effective dosage for physique- or performance-enhancing purposes would be around 5 mg per day. This would be taken for no longer than 4-6 weeks, in an effort to avoid significant liver strain or virilizing side effects. Given that complete separation of anabolic and androgenic effect has not been achieved with any steroid, this agent is still capable of producing virilizing activity given the right dose or individual sensitivity.
Methepitiostane is currently only produced as an underground/designer steroid.
Wlliam Llewellyn (2017) - Anabolics